Noradrenergic Function in Panic Anxiety: Effects of Yohimbine in Healthy Subjects and Patients With Agoraphobia and Panic Disorder

Archives of General Psychiatry

Volumn 41, Issue 8, 1984, Pages 751-763

  Charney, Dennis S ^a   Heninger, George R ^a   Breier, Alan ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; AMITRIPTYLINE; DESIPRAMINE; DIAZEPAM; ISOPRENALINE; NORADRENALIN; OXIDOPAMINE; PLACEBO; YOHIMBINE;

AGORAPHOBIA; ANXIETY; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG THERAPY; HEART; HEART RATE; HUMAN; NORADRENERGIC SYSTEM; PANIC; PULSE RATE; THERAPY;

ADULT; AGED; AGORAPHOBIA; ANXIETY DISORDERS; BLOOD PRESSURE; FEAR; HEART RATE; HUMAN; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGE; NOREPINEPHRINE; PANIC; PULSE; RECEPTORS, ADRENERGIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; YOHIMBINE;

EID: 0021249631     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1984.01790190025003     Document Type: Article

References (105)

1. Marks I, Lader M: Anxiety states (anxiety neurosis): A review. J Nerv Ment Dis 1973;150:3-18.
2. Schapira K, Roth M, Kerr TA, Gurney C: The prognosis of affective disorders: The differentiation of anxiety states from depressive illnesses. Br J Psychiatry 1972;121:175-181.
3. Braestrup C, Nielsen M: Benzodiazepine receptors, in Iverson L, Iverson SD, Snyder SA (eds): Handbook of Psychopharmacology. New York, Plenum Publishing Corp, 1983, vol 17, pp 285-384.
4. Redmond DE Jr: New and old evidence for the involvement of a brain norepinephrine system in anxiety, in Fann WE (ed): The Phenomenology and Treatment of Anxiety. New York, Spectrum Press, 1979, pp 153-203.
5. Tallman JF, Paul SM, Skolnick P, Gallager DW: Receptors for the age of anxiety. Science 1980;207:274-281.
6. Phillis JW, Wu PH: The role of adenosine and its nucleotides in central synaptic transmission. Prog Neurobiol 1981;16:187-239.
7. Clark TK: The locus coeruleus in behavior regulation: Evidence for behavior-specific versus general involvement. Behav Neurol Biol 1979;25:271-300.
8. McNaughton N, Mason ST: The neurophysiology and neuropharmacology of the dorsal ascending noradrenergic bundle: A review. Prog Neurobiol 1980;14:157-219.
9. Mason ST: Noradrenaline in the brain: Progress in theories of behavioural function. Prog Neurobiol 1981;16:263-303.
10. Foote SL, Bloom FE, Aston-Jones G: Nucleus locus coeruleus: New evidence of anatomical and physiological specificity. Physiol Rev 1983;63:844-914.
11. Moore RY, Bloom FE: Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems. Ann Rev Neurosci 1979;2:113-168.
12. Starke K, Borowski E, Endo T: Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Eur J Pharmacol 1975;34:385-388.
13. Cedarbaum JM, Aghajanian GK: Noradrenergic neurons of the locus coeruleus: Inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res 1976;112:413-419.
14. Cedarbaum JM, Aghajanian GK: Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization. Eur J Pharmacol 1977;44:375-385.
15. Andrade R, Aghajanian GK: Single cell activity in the noradrenergic A-5 region: Responses to drugs and peripheral manipulations of blood pressure. Brain Res 1982;242:125-135.
16. Segal M: Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. J Physiol 1979;286:401-415.
17. Guyenet PG, Aghajanian GK: Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides. Brain Res 1977;136:178-184.
18. Guyenet PG, Aghajanian GK: ACh, substance P and met-enkephalin in the locus coeruleus: Pharmacological evidence for independent sites of action. Eur J Pharmacol 1979;53:319-328.
19. Bird SJ, Kuhar MJ: Iontophoretic application of opiates to the locus coeruleus. Brain Res 1977;122:523-533.
20. Grant SJ, Huang YH, Redmond DE Jr: Benzodiazepines attenuate single unit activity in the locus coeruleus. Life Sci 1980;27:2231-2236.
21. Sanghera MK, McMillen BA, German DC: Buspirone, a non-benzodiazepine anxiolytic increases locus coeruleus noradrenergic neuronal activity. Eur J Pharmacol 1983;86:107-110.
22. Nyback HV, Walters JR, Aghajanian GK, Roth RH: Tricyclic antidepressants: Effects on the firing rate of brain noradrenergic neurons. Eur J Pharmacol 1975;32:302-312.
23. Svensson TH, Usdin T: Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: α-Receptor mediation. Science 1978;202:1089-1091.
24. Aghajanian GK: Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature 1978;276:186-188.
25. Soffer A: Regatine and benadine in the diagnoses of pheochromocytoma. Med Clin North Am 1954;38:375-384.
26. Holmberg G, Gershon S: Autonomic and psychiatric effects of yohimbine hydrochloride. Psychopharmacologia 1961;2:93-106.
27. Charney DS, Heninger GR, Sternberg DE: Assessment of alpha-2 adrenergic autoreceptor function in humans: Effects of oral yohimbine. Life Sci 1982;30:2033-2041.
28. Scatton B, Zivkivic B, Dedek J: Antidopamine properties of yohimbine. J Pharmacol Exp Ther 1980;215:494-499.
29. Redmond DE Jr, Huang YH: New evidence for a locus coeruleusnorepinephrine connection with anxiety. Life Sci 1979;25:2149-2162.
30. Mason ST, Fibiger HC: Anxiety: The locus coeruleus disconnection. Life Sci 1979;25:2141-2147.
31. Mason ST, Fibiger HC: Noradrenaline, fear, and extinction. Brain Res 1979;165:47-56.
32. Barchas JD, Freedman DX: Brain amines: Response to physiological stress. Biochem Pharmacol 1963;12:1225-1238.
33. Bliss EL, Wilson VB, Zwanziger J: Changes in brain norepinephrine in self-stimulating and aversive animals. J Psychiatr Res 1966;4:59-63.
34. Bliss EL, Zwanziger J: Brain amines and emotional stress. J Psychiatr Res 1966;4:189-198.
35. Freedman DX: Psychomimetic drugs and brain biogenic amines. Am J Psychiatry 1963;119:843-850.
36. Corrodi H, Fuxe J, Lidbrink P: Minor tranquilizers, stress and central catecholamine neurons. Brain Res 1971;29:1-16.
37. Lidbrink P, Corrodi H, Fuxe K: Barbiturates and meprobamate: Decreases in catecholamine turnover of central dopamine and noradrenaline neuronal systems and the influence of immobilization stress. Brain Res 1972;45:507-524.
38. Maynert EW, Levi R: Stress-induced release of brain norepinephrine and its inhibition by drugs. J Pharmacol Exp Ther 1964;143:90-95.
39. Stolk JM, Barchas JD, Goldstein M: A comparison of psychomimetic drug effects on rat brain norepinephrine metabolism. J Pharmacol Exp Ther 1974;189:42-50.
40. Roth KA, Mefford IM, Barchas JD: Epinephrine, norepinephrine, dopamine and serotonin: Differential effects of acute and chronic stress on regional brain amines. Brain Res 1982;239:417-424.
41. Glavin G, Tanaka M, Tsuda A, Kohno Y, Hoaki Y, Nagansaki N: Regional rat brain noradrenaline turnover in response to restraint stress. Pharmacol Biochem Behav 1983;19:287-290.
42. Redmond DE Jr, Huang YH, Snyder DR, Maas JW: Behavioral effects of stimulation of the locus coeruleus in the stumptail monkey (Macaca arctoides). Brain Resp 1976;116:502-510.
43. Redmond DE Jr, Huang YH, Snyder DR, Maas JW, Baulu J: Behavioral changes following lesions of the locus coeruleus in Macaca arctoides. Neurosci Abst 1976;1:472.
44. Huang YH, Redmond DE Jr, Snyder DR, Maas JW: Loss of fear following bilateral lesions of the locus coeruleus in the monkey. Neurosci Abst 1976;2:573.
45. Gold MS, Redmond DE Jr: Pharmacological activation and inhibition of noradrenergic activity alter specific behaviors in nonhuman primates. Neurosci Abst 1977;3:250.
46. Breggin PR: The psychophysiology of anxiety: With a review of literature concerning adrenaline. J Nerv Ment Dis 1964;109:558-568.
47. Lader M: The peripheral and central role of the catecholamines in the mechanisms of anxiety. Int Pharmacopsychiatry 1974;9:125-137.
48. Charney DS, Heninger GR, Redmond DE Jr: Noradrenergic function and human anxiety. Read before the 136th annual meeting of the American Psychiatric Association, New York, May 1983.
49. Charney DS, Heninger GR, Sternberg DE, Landis H: Abrupt discontinuation of tricyclic antidepressant drugs: Evidence of noradrenergic hyperactivity. Br J Psychiatry 1982;141:377-386.
50. Post RM, Lake CR, Jimerson DC, Bunney WE, Wood JH, Ziegler MG, Goodwin FK: CSF norepinephrine in affective illness. Am J Psychiatry 1978;135:907-912.
51. Sweeney DR, Maas JW, Heninger GR: State anxiety and urinary MHPG. Arch Gen Psychiatry 1978;35:1418-1423.
52. Wyatt RJ, Portnoy B, Kupfer DJ, Snyder F, Engelman K: Resting catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 1971;24:65-70.
53. Ko GN, Elsworth JD, Roth RH, Rifkin BG, Leigh H, Redmond E Jr: Panic-induced elevation of plasma MHPG in phobic-anxious patients: Effects of clonidine or imipramine. Arch Gen Psychiatry 1983;40:425-430.
54. Minneman KP: Peripheral catecholamine administration does not alter cerebral β-adrenergic receptor density. Brain Res 1983;264:328-331.
55. Hardebo JE, Owman C: Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. Ann Neurol 1980;8:1-11.
56. MacKenzie ET, McCulloch J, O'Keane M, Pickard JD, Harper AM: Cerebral circulation and norepinephrine: Relevance of the blood-brain barrier. Am J Physiol 1976;231:483-488.
57. American Psychiatric Association Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC, American Psychiatric Association, 1980.
58. Klein DF, Raskin J (eds): Anxiety: New Research and Changing Concepts. New York, Raven Press, 1981.
59. Spitzer RL, Endicott J: Schedule for Affective Disorders and Schizophrenia. New York, New York State Psychiatric Institute, 1978.
60. Hamilton M: Diagnosis and ratings of anxiety. Br J Psychiatry 1969;3:76-79.
61. Zitrin GM, Klein DF, Woerner MG, Ross DC: Treatment of phobias: Comparison of imipramine and placebo. Arch Gen Psychiatry 1983;40:125-138.
62. Dekirmenjian H, Maas JW: MHPG in plasma. Clin Chim Acta 1974;52:203-208.
63. Maas JW, Hattox SE, Roth RH: The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG). Brain Res 1976;118:167-174.
64. Maas JW, Hattox SE, Landis DH: Differential effects on brain catecholamines by Debrisoquin. Biochem Pharmacol 1979;28:3153-3156.
65. Mignot E, Laude D, Elghozi J, LeQuan-Bui KH, Meyer P: Central administration of yohimbine increases free 3-methoxy-4-hydroxyphenylglycol in the cerebrospinal fluid of the rat. Eur J Pharmacol 1982;83:135-138.
66. Faroum F, Mayer-Schwing J, Potkin SG, Wyatt RJ: Presence of free sulfate, and glucuronide conjugated MHPG in human brain, cerebrospinal fluid, and plasma. Brain Res 1977;125:333.
67. Maas JW, Landis H, Dekirmenjian H: The occurrence of free vs conjugated MHPG in nonhumans and human primate brain. Psychopharmacol Commun 1976;2:403-410.
68. Maas JW, Hattox SE, Green NM, Landis DH: MHPG production by human in vivo. Science 1979;287:1025.
69. Maas JW, Hattox SE, Landis DH, Roth RH: A direct method for studying MHPG by brain in awake animals. Eur J Pharmacol 1977;46:221-228.
70. Elsworth JD, Redmond DE Jr, Roth RH: Plasma and cerebrospinal fluid MHPG as indices of brain norepinephrine metabolites in primates. Brain Res 1982;235:115-124.
71. Jimerson DC, Ballenger JC, Lake CR, Post RM, Goodwin FK, Kopin IJ: Plasma and CSF in normals. Psychopharmacol Bull 1981;17:86-87.
72. Leckman MF, Maas JW, Redmond DE Jr, Heninger GR: Effects of oral clonidine on plasma MHPG in man. Life Sci 1980;26:2179-2185.
73. Charney DS, Galloway MP, Heninger GR: The effects of caffeine on plasma MHPG subjective anxiety, autonomic symptoms and blood pressure in healthy humans. Life Sci 1984;35:135-144.
74. Kopin J, Blombery P, Ebert MH, Gordon EK, Jimerson DC, Markey SP, Polinsky RJ: Disposition and metabolism of MHPG-CD3 in humans: Plasma MHPG as the principal pathway of norepinephrine metabolism and as an important determinant of CSF levels of MHPG. Read before the Nobel Conference, Stockholm, June 1982.
75. Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ: Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 1983;219:73-75.
76. Tung CS, Onuora CO, Robertson D, Goldberg MR: Hypertensive effect of yohimbine following selective injection into the nucleus tractus solitarii of normotensive rats. Brain Res 1983;277:193-195.
77. Kubo T, Yoshimi M: Pharmacological characterization of the α-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat. Arch Pharmacol 1981;317:120-125.
78. Bousquet P, Schwartz J: Commentary: Alpha-adrenergic drugs: Pharmacological tools for the study of the central vasomotor control. Biochem Pharmacol 1983;32:1459-1465.
79. Brown DA, Caulfield MP: Hyperpolarizing α2-adrenoceptors in rat sympathetic ganglia. Br J Pharmacol 1979;65:435-445.
80. Timmermans PB, VanZwieten PA: Mini-review of the postsynaptic α2-adrenoreceptor. J Auton Pharmacol 1981;1:171-183.
81. Langer SZ: Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981;32:337-362.
82. Foote SL, Aston-Jones G, Bloom FE: Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci USA 1980;77:3033-3037.
83. Nashold BS Jr, Wilson WP, Slaughter G: The midbrain and pain. Adv Neurol 1974;4:191-196.
84. Cameron OG, Hollingsworth PJ, Nesse RM, Curtis GC, Smith CB: Platelet α2 adrenergic receptors and plasma catecholamines in panic anxiety before and after imipramine treatment. Read before the annual meeting of the American Psychiatric Association, New York, May, 1983.
85. Szabadi E: Review: Adrenoceptors on central neurones: Microelectrophoretic studies. Neuropharmacology 1979;18:831-843.
86. Aghajanian GK, Rogawski MA: The physiological role of α-adrenoceptors in the CNS: New concepts from single-cell studies. Trends Pharmacol Sci 1983;315-317.
87. Aghajanian GK: The physiology of central alpha and beta adrenoceptors, in Usdin E (ed): Catecholamines. New York, Alan R Liss Inc, in press.
88. Andrade R, Aghajanian GK: Locus coeruleus activity in vitro: Intrinsic regulation by a calcium-dependent potassium conductance but not alpha-2 adrenoceptors. J Neurosci 1984;4:161-170.
89. Guyent PG, Cabot JB: Inhibition of sympathetic preganglionic neurons by catecholamines and clonidine: Mediation by an alpha adrenergic receptor. J Neurosci 1981;1:908-917.
90. Rogawski MA, Aghajanian GK: Modulation of lateral geniculate neuronal excitability by noradrenaline microiontophoresis or locus coeruleus stimulation. Nature 1980;287:731-734.
91. Vandermaelen CP, Aghajanian GK: Intracellular studies showing modulation of facial motoneuron excitability by serotonin. Nature 1980;287:346-347.
92. Woodward PJ, Moises HC, Waterhouse BD, Hoffer BJ, Freedman R: Modulatory actions of norepinephrine in the central nervous system. Fed Proc 1979;38:2109-2116.
93. Madison DV, Nicoll RA: Noradrenaline blocks accommodation of pyramidal cell discharge in the hippocampus. Nature 1982;299:636-638.
94. Haas HL, Konnerth A: Histamine and noradrenaline decrease calcium-activated potassium conductance in hippocampal pyramidol cells. Nature 1983;302:432-434.
95. Young WS III, Kuhar MJ: Noradrenergic α-1 and α-2 receptors: Light microscopic autoradiographic localization. Proc Natl Acad Sci USA 1980;77:1696-1700.
96. Palacios JM, Kuhar MJ: Beta-adrenergic-receptor localization by light microscopic autoradiography. Science 1980;208:1378-1380.
97. Young WS III, Kuhar MJ: Anatomical mapping of clonidine (α-2 noradrenergic) receptors in rat brain: Relationship to function, in Lai H, Fielding S (eds): Psychopharmacology of Clonidine. New York, Alan R Liss Inc, 1981, pp 41-52.
98. Palacios JM, Kuhar MJ: Beta adrenergic receptor localization in rat brain by light microscopic autoradiography. Neurochem Int 1982;4:473-490.
99. Rainbow TC, Biegon A: Quantitative autoradiography of H prazosin binding sites in rat forebrain. Neurosci Lett 1983;40:221-226.
100. Charney DS, Heninger GR, Redmond DE Jr: Yohimbine induced anxiety and increased noradrenergic function in humans: Effects of diazepam and clonidine. Life Sci 1983;33:19-29.
101. Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59.
102. Charney DS, Menkes DB, Heninger GR: Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 1981;38:1160-1180.
103. Charney DS, Heninger GR, Sternberg DE, Roth RH: Plasma MHPG in depression: Effects of acute and chronic desipramine treatment. Psychiatry Res 1981;5:217-229.
104. Charney DS, Heninger GR, Sternberg DE: Alpha-2 adrenergic receptor sensitivity and the mechanism of action of antidepressant therapy: The effect of long-term amitriptyline treatment. Br J Psychiatry 1983;142:265-275.
105. Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ: Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients. Arch Gen Psychiatry 1982;39:1025-1028.